Welcome to LookChem.com Sign In|Join Free

CAS

  • or

106475-47-2

Post Buying Request

106475-47-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

106475-47-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 106475-47-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,4,7 and 5 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 106475-47:
(8*1)+(7*0)+(6*6)+(5*4)+(4*7)+(3*5)+(2*4)+(1*7)=122
122 % 10 = 2
So 106475-47-2 is a valid CAS Registry Number.

106475-47-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 4-anilino-2-methylsulfanylpyrimidine-5-carboxylate

1.2 Other means of identification

Product number -
Other names 2-methanesulfanyl-4-phenylamino-pyrimidine-5-carboxylic acid ethyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:106475-47-2 SDS

106475-47-2Relevant articles and documents

Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001

Apuy, Julius,Bahmanyar, Sogole,Benish, Brent,Bennett, Brydon L.,Blease, Kate,Canan, Stacie S.,Condroski, Kevin,Delgado, Mercedes,Elsner, Jan,Erdman, Paul,Haelewyn, Jason,Hilgraf, Robert,Khambatta, Godrej,Lebrun, Laurie,McCarrick, Meg,Moghaddam, Mehran F.,Mortensen, Deborah S.,Nagy, Mark A.,Norris, Stephen,Paisner, David,Romanow, William J.,Satoh, Yoshitaka,Tikhe, Jayashree,Xu, Li,Yoon, Won

supporting information, p. 18193 - 18208 (2021/12/27)

As a result of emerging biological data suggesting that within the c-Jun N-terminal kinase (JNK) family, JNK1 and not JNK2 or JNK3 may be primarily responsible for fibrosis pathology, we sought to identify JNK inhibitors with an increased JNK1 bias relative to our previous clinical compound tanzisertib (CC-930). This manuscript reports the synthesis and structure-activity relationship (SAR) studies for a novel series of JNK inhibitors demonstrating an increased JNK1 bias. SAR optimization on a series of 2,4-dialkylamino-pyrimidine-5-carboxamides resulted in the identification of compounds possessing low nanomolar JNK inhibitory potency, overall kinome selectivity, and the ability to inhibit cellular phosphorylation of the direct JNK substrate c-Jun. Optimization of physicochemical properties in this series resulted in compounds that demonstrated excellent systemic exposure following oral dosing, enabling in vivo efficacy studies and the selection of a candidate for clinical development, CC-90001, which is currently in clinical trials (Phase II) in patients with idiopathic pulmonary fibrosis (NCT03142191).

5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES

-

Page/Page column 26, (2012/11/08)

The present invention relates to 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives, to their preparation and to their therapeutic use.

Pyridopyrimidinone derivatives for treatment of neurodegenerative disease

-

, (2008/06/13)

This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-di

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 106475-47-2